Skip to main content
IMUX
NASDAQ Life Sciences

Immunic Lays Out Catalyst-Rich Path to Market for Lead MS Drug in Updated Investor Deck

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$14.6
Mkt Cap
$199.419M
52W Low
$5.062
52W High
$15.84
52W Position info
188% above low
Off High info
7.8% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

IMUX has more than doubled off its 52-week low of $5.062.

Summary

Immunic's updated investor presentation charts a clear regulatory course for its lead MS drug, with pivotal Phase 3 data due by end of 2026 and an NDA submission in mid-2027. A Phase 3 trial in progressive MS is also slated to begin later this year.


Key Events · Product Development and Regulatory · IMUX

  • Phase 3 ENSURE Data by Year-End 2026

    Fully enrolled with a combined 2,221 patients, both ENSURE-1 and ENSURE-2 trials in relapsing MS are on track to deliver top-line results by the end of 2026.

  • NDA Submission Targeted for Mid-2027

    Assuming positive ENSURE data, a New Drug Application is planned for submission in the U.S. by mid-2027, setting the stage for potential approval in 2028.

  • Phase 3 Progressive MS Trial Initiation in 2026

    Encouraged by Phase 2 CALLIPER data that signaled disability improvement, the company expects to launch a Phase 3 trial in progressive MS later this year.

  • Cash Runway into Late 2027

    Financial guidance is reiterated, with the current funding position expected to support operations into late 2027, comfortably covering the pivotal ENSURE readout.


Analysis · IMUX · Life Sciences

An updated investor presentation from Immunic maps out the road to market for vidofludimus calcium in multiple sclerosis. With both Phase 3 ENSURE trials in relapsing MS fully enrolled, top-line data are expected by year-end 2026, paving the way for a mid-2027 NDA submission and potential U.S. approval in 2028. The deck also reveals plans to kick off a Phase 3 trial in progressive MS later this year, broadening the drug's commercial reach. For a company with a $199M market cap and a cash runway into late 2027, these timelines turn the next 18 months into a decisive value-inflection window.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMUX was trading at $14.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.4M. The 52-week trading range was $5.06 to $15.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMUX - Latest Insights

IMUX
Nov 13, 2026, 7:12 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.71
Real-time Price: $7.50 info
Change: -$0.210 (-3%) info
Market Cap: $102.606M info
IMUX
Nov 05, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.20
Real-time Price: $7.50 info
Change: -$0.700 (-9%) info
Market Cap: $102.606M info
IMUX
Sep 09, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.26
Real-time Price: $7.50 info
Change: -$5.76 (-43%) info
Market Cap: $102.606M info
IMUX
Aug 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.10
Real-time Price: $7.50 info
Change: -$6.60 (-47%) info
Market Cap: $102.606M info
IMUX
Aug 11, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $7.50 info
Change: -$6.60 (-47%) info
Market Cap: $102.606M info